The term “deprescribing,” refers to a process of pharmacologic regimen optimization through reduction or cessation of medications for which benefits no longer outweigh risks. Alarming rates of polypharmacy, growing appreciation of long-term side effects, and a focus on client-centered practice present specific indications for deprescribing in psychiatry. The presenters discuss how deprescribing might be adapted for and implemented in psychiatry, identify potential barriers, and make recommendations for future directions.Polypharmacy is a clinical challenge because the health care system is geared toward starting medications, not reducing or stopping them, and guidelines typically include recommendations for initiating medications, but not stopping them. Although any medication may offer potential benefit, each also has potential harm. When combined, the risk of interactions with other medications or conditions or cumulative harms can outweigh the benefits.The five steps to individualize deprescribing practices to each patient are (1) to identify potentially inappropriate medications; (2) to determine if the medication dosage can be reduced or the medication stopped; (3) to plan tapering; (4) to monitor (for discontinuation symptoms or the need to restart) and support the patient; and (5) to document outcomes.Thus through thia symposium we aim to discuss about deprescribing and its relevance in the field of Psychiatry so that yhe knowledge can be translated and integrated in current practices thus promoting better patient care and therapeutic alliance.